CONNECT WITH US
Fintech

Fintech

J&J Spotlights FDA-Approved Surgical Robot Amid $100 Billion Revenue Push

PYMNTS – Fintech logo

Published on

Add as a preferred source on Google
J&J Spotlights FDA-Approved Surgical Robot Amid $100 Billion Revenue Push

Regulatory approval of a new Johnson & Johnson tool opens a new category in surgical robotics, the MedTech company said in a presentation released Tuesday (Oct. 13) in conjunction with its third-quarter earnings call.

Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

Johnson & Johnson’s new OTTAVA table-integrated soft tissue robotic system achieved U.S. Food and Drug Administration market authorization during the quarter. The authorization spans 10 general surgery procedures, including gastric bypass and hiatal hernia repair, according to the presentation.

In a Tuesday press release, Johnson & Johnson Chairman and CEO Joaquin Duato characterized OTTAVA as “one of our most transformative MedTech innovations.”

Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

Duato said that when the FDA granted de novo authorization to OTTAVA in July, the tool became the world’s first table-integrated soft tissue robotic system to achieve that.

“This is one of the most significant MedTech innovations we will bring to market this decade,” Duato said. “OTTAVA’s unique architecture, automated features and next-generation robotic instruments help address surgeon needs for operating room space and better surgical workflows. Its connection to our open digital ecosystem, Polyphonic, turns procedure data into actionable insights for clinicians.”

Johnson & Johnson gained this approval during a quarter in which its sales grew 5.9% and reached $25.4 billion, according to the press release.


Source link
Related Topics:Fintech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.